The efficacy and safety of dienogest in a reduction of pelvic pain-induced by adenomyosis
Mekan Orazov (RU), Victor Radzinskiy (RU), Marina Khamoshina (RU), Marina Lebedeva (RU)
[Orazov] RUSSIAN PEOPLE’S FRIENDSHIP UNIVERSITY, MOSCOW, RUSSIA , [Radzinskiy ] RUSSIAN PEOPLE’S FRIENDSHIP UNIVERSITY, MOSCOW, RUSSIA , [Khamoshina] RUSSIAN PEOPLE’S FRIENDSHIP UNIVERSITY, MOSCOW, RUSSIA , [Lebedeva] RUSSIAN PEOPLE’S FRIENDSHIP UNIVERSITY, MOSCOW, RUSSIA
Adenomyosis is a common gynecological condition characterized by the diffuse or local growth of endometrial glandular tissue, which invades the muscular layer of the uterus. The main symptoms of adenomyosis include dysmenorrhea, menorrhagia, infertility, chronic pelvic pain syndrom. Medical treatments of pelvic pain caused by adenomyosis may represent hormonal therapies but are associated with adverse events impacting long-term use and adherence this is why the use of drugs with minimal systematic side effects is the target basis of the modern therapy of pelvic pain associated with adenomyosis. The aim of the study was to research immediate and remote results of the relief of chronic pelvic pain in women of reproductive age with adenomyosis, with the use of the dienogest 2mg per day. Materials and methods:A total of 120 reproductive age patients (31–45 years). Results: Of the 120 (n=120) patients 116 (96,7%) completed the study. 4 (3,3%) patients refused from the study due to the non-effectiveness of treatment within the 1st month. In the main group with pain of intensity, improvement was observed already at the end of the 1st (33.6%) month in 39 patients, at the end of the 2nd month – in 48 ( 41,4%) patients, and in the remaining 11 (9,5%) patients - at the end of the 3rd month, thus a complete pain syndrome reduction was registered already at the end of the 3rd month in all patients. Conclusion: Thus, the obtained results allowed to confirm the possibility of using dienogest in the treatment of pelvic pain syndrome associated with adenomyosis. This is a cost effective, reversible and long-term treatment for women with pelvic pain associated by adenomyosis.